文献速递淋巴瘤

Odronextamab(一种人源CD20×CD3双特异性抗体)治疗CD20阳性B细胞恶性肿瘤患者(ELM-1):单臂、多中心、1期试验中复发或难治性非霍奇金淋巴瘤队列的结果

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
PubMed 文献 · Lancet Haematol · 2022-04-01

ELM-1是一项在美国和德国10个学术中心开展的单臂、多中心、1期剂量递增和剂量扩展试验,评估odronextamab在145例既往接受过CD20靶向抗体治疗的复发或难治性B细胞非霍奇金淋巴瘤患者中的安全性和抗肿瘤活性。中位随访4.2个月,客观缓解率为51%(95% CI 42-59;142例中72例),滤泡性淋巴瘤(剂量≥5 mg)为91%(95% CI 75-98;32例中29例),弥漫大B细胞淋巴瘤(无CAR-T史,剂量≥80 mg)为53%(15例中8例)。

要点

  • 145例重度经治复发/难治B细胞非霍奇金淋巴瘤患者中,客观缓解率为51%(95% CI 42-59;142例中72例)。
  • 滤泡性淋巴瘤(剂量≥5 mg)客观缓解率91%(95% CI 75-98;32例中29例),完全缓解率72%(95% CI 53-86;32例中23例)。
  • 细胞因子释放综合征和神经系统治疗中出现的不良事件以低级别为主,未导致治疗中止。

核心结论

  • Odronextamab单药治疗显示出可控的安全性和令人鼓舞的初步活性,包括在重度经治B细胞非霍奇金淋巴瘤患者中的持久缓解,支持在2期和3期试验中进一步开展临床研究。

研究设计与样本

  • 单臂、多中心、1期剂量递增和剂量扩展(ELM-1)试验,在美国和德国10个学术中心开展。
  • 纳入145例既往接受过CD20靶向抗体治疗的CD20阳性复发或难治性B细胞恶性肿瘤患者(剂量递增94例,剂量扩展51例)。
  • 患者接受静脉odronextamab,第1周期采用逐步递增给药方案,第2-4周期每周一次目标剂量0.1 mg至320 mg(每周期21天),第4周期后每2周维持治疗直至疾病进展或不可接受毒性。
  • 主要终点为安全性和剂量限制性毒性以确定最大耐受剂量或2期剂量,客观缓解率为次要终点。

主要发现

  • 中位年龄67.0岁(IQR 57.0-73.0);101例(70%)男性,44例(30%)女性;119例(82%)为White,132例(91%)为非Hispanic或Latino。
  • 42例(29%)既往接受过CAR-T治疗,119例(82%)对末线治疗难治;中位既往治疗线数3(IQR 2-5)。
  • 剂量递增期间odronextamab最高给药剂量为320 mg每周一次,未观察到剂量限制性毒性。
  • 最常见≥3级治疗中出现的不良事件为贫血(36例[25%])、淋巴细胞减少(28例[19%])、低磷血症(27例[19%])、中性粒细胞减少(27例[19%])和血小板减少(20例[14%])。
  • 89例(61%)发生严重治疗中出现的不良事件,最常见为细胞因子释放综合征(41例[28%])、发热(11例[8%])、肺炎(9例[6%])和输注相关反应(6例[4%]);4例死亡被认为与治疗相关。

关键数值与推荐

  • 滤泡性淋巴瘤1-3a级患者的扩展推荐剂量为80 mg,弥漫大B细胞淋巴瘤患者为160 mg。
  • 总体客观缓解率为51%(95% CI 42-59;142例中72例)。
  • 滤泡性淋巴瘤接受odronextamab剂量≥5 mg的患者客观缓解率为91%(95% CI 75-98;32例中29例),完全缓解率为72%(95% CI 53-86;32例中23例)。
  • 无既往CAR-T治疗的弥漫大B细胞淋巴瘤接受剂量≥80 mg的患者客观缓解率为53%(15例中8例),所有缓解均为完全缓解。
  • 有既往CAR-T治疗的弥漫大B细胞淋巴瘤接受剂量≥80 mg的患者客观缓解率为33%(30例中10例),完全缓解率为27%(30例中8例)。

临床怎么用

  • Odronextamab单药治疗在重度经治复发或难治性B细胞非霍奇金淋巴瘤患者中显示出可控的安全性和令人鼓舞的初步活性。
  • 作者认为结果支持在2期和3期试验中进一步开展临床研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells. We aimed to evaluate the safety and antitumour activity of odronextamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. METHODS: This single-arm, multicentre, phase 1, dose-escalation and dose-expansion (ELM-1) trial was conducted at ten academic sites across the USA and Germany. Patients aged 18 years or older with CD20-positive relapsed or refractory B-cell malignancies who previously received CD20-directed antibody therapy and who had at least one measurable lesion, and an ECOG performance status of 0 or 1 were included. Patients received intravenous odronextamab, according to a step-up dosing schedule in cycle 1, followed by treatment once per week at target doses ranging from 0·1 mg to 320 mg during cycles 2-4 (each cycle was 21 days). After cycle 4, maintenance treatment occurred every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint of safety was assessed by the incidence of adverse events and dose-limiting toxicities to determine the maximum tolerated dose or phase 2 dose of odronextamab, or both. Preliminary antitumour activity, as measured by objective response rate, was a secondary endpoint. This study is registered with ClinicalTrials.gov, NCT02290951. FINDINGS: From Feb 4, 2015, to Sept 25, 2021, 145 heavily pretreated patients (median of 3 (IQR 2-5] previous therapies) were enrolled (94 to the dose-escalation and 51 to the dose-expansion part of the study). The median age of patients was 67·0 years (IQR 57·0-73·0); 101 (70%) were male and 44 (30%) were female; most participants were White (119 [82%]) and not Hispanic or Latino (132 [91%]). 42 (29%) patients received previous CAR T therapy and 119 (82%) were refractory to the last line of therapy. Median duration of follow-up was 4·2 months (IQR 1·5-11·5). During dose escalation, odronextamab was administered up to the maximum dose of 320 mg once per week and no dose-limiting toxicities were observed. The recommended dose for expansion in patients with follicular lymphoma grade 1-3a was 80 mg and was 160 mg for patients with diffuse large B-cell lymphoma. Cytokine release syndrome and neurological treatment-emergent adverse events were predominantly low grade and did not result in treatment discontinuation. The most common grade 3 or worse treatment-emergent adverse events were anaemia (36 [25%]), lymphopenia (28 [19%]), hypophosphataemia (27 [19%]), neutropenia (27 [19%]), and thrombocytopenia (20 [14%]). Serious treatment-emergent adverse events occurred in 89 (61%) of 145 patients; the most frequent were cytokine release syndrome (41 [28%]), pyrexia (11 [8%]), pneumonia (nine [6%]), and infusion-related reaction (six [4%]). Four deaths were considered related to treatment (gastric perforation in a patient with gastric involvement by lymphoma, lung infection, pneumonia, and tumour-lysis syndrome). Objective response rate was 51% (95% CI 42-59; 72 of 142). In patients with follicular lymphoma who received odronextamab doses of 5 mg or higher, the objective response rate was 91% (95% CI 75-98; 29 of 32) and the complete response rate was 72% (95% CI 53-86; 23 of 32). In patients with diffuse large B-cell lymphoma without previous CAR T-cell therapy who received doses of 80 mg or higher, the objective response rate was 53% (eight of 15) and all responses were complete responses. In patients with diffuse large B-cell lymphoma who had previous CAR T-cell therapy and received doses of 80 mg or higher, the objective response rate was 33% (ten of 30) and complete response rate was 27% (eight of 30). INTERPRETATION: Odronextamab monotherapy showed a manageable safety profile and encouraging preliminary activity, including durable responses in heavily pretreated patients with B-cell non-Hodgkin lymphoma, supporting further clinical investigation in phase 2 and 3 trials. FUNDING: Regeneron Pharmaceuticals.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022. PMID: 35366963. doi:10.1016/S2352-3026(22)00072-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。